Katherine Fitzgerald to Genetic Vectors
This is a "connection" page, showing publications Katherine Fitzgerald has written about Genetic Vectors.
Connection Strength
1.044
-
Fitzgerald K, Stephan SB, Ma N, Wu QV, Stephan MT. Liquid foam improves potency and safety of gene therapy vectors. Nat Commun. 2024 May 28; 15(1):4523.
Score: 0.565
-
Fitzgerald KA. Integr-ating IL-1 alpha in antiviral host defenses. Immunity. 2009 Jul 17; 31(1):7-9.
Score: 0.202
-
Keeler AM, Zhan W, Ram S, Fitzgerald KA, Gao G. The curious case of AAV immunology. Mol Ther. 2025 May 07; 33(5):1946-1965.
Score: 0.150
-
Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, Gao G. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021 01 04; 131(1).
Score: 0.112
-
DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004 Aug 27; 279(35):36570-8.
Score: 0.009
-
Brint EK, Fitzgerald KA, Smith P, Coyle AJ, Gutierrez-Ramos JC, Fallon PG, O'Neill LA. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction. J Biol Chem. 2002 Dec 20; 277(51):49205-11.
Score: 0.008